Metabolic Modulation as treatment of acute heart failure in patients
Phase 1
- Conditions
- acute decompensated heart failureMedDRA version: 8.1Level: LLTClassification code 10000803Term: Acute heart failure
- Registration Number
- EUCTR2006-004485-14-DK
- Lead Sponsor
- Aarhus University Hospital, Skejby sygehus
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
seriuos Acute heart failure
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Age <18 or >85, Recent myocardial infarction (<6 weeks), renal failure, Insulintreated diabetes, Gastric Ulcer, pregnancy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To test the the potential of and the metabolic consequences of acipimox-treatment in acute heart failure and the effects on central hemodynamics;Secondary Objective: to evaluate Non invasive cardiac output measuerments in acute decompensated heartfailure<br>;Primary end point(s): myocardial glucose- and free fatty acid-extraction<br>Invasive cardiac index<br>Pulmonary capillary wedge pressure (PCWP)<br>
- Secondary Outcome Measures
Name Time Method